Interpace Biosciences Inc. (IDXG)

Overview

Interpace Biosciences, Inc. stands at the forefront of molecular diagnostic tests and services aimed at evaluating cancer risk, providing critical insights in the United States. Its specialization in bioinformatics and pathology services caters to the pressing needs in oncology, particularly in understanding and diagnosing cancer risks. Originally established in 1986 and initially known as Interpace Diagnostics Group, Inc., the company underwent a rebranding to Interpace Biosciences, Inc. in November 2019, marking a new era of its operational focus. With its headquarters nestled in Parsippany, New Jersey, Interpace Biosciences has become a pivotal player in the healthcare sector, primarily serving physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals with its innovative diagnostics solutions.

Products and Services

• PancraGEN

  This pancreatic cyst and pancreaticobiliary solid lesion genomic test is specialized for the diagnosis and prognosis of pancreatic cancer. PancraGEN uses advanced genomic analysis to guide clinical management of pancreatic cysts and lesions, providing essential information on cancer risk and guiding treatment decisions.

• PanDNA

  As a molecular-only version of PancraGEN, PanDNA offers a targeted approach to analyzing pancreatic cysts, focusing solely on molecular markers to assess the risk of malignancy. This option provides a strategic tool for clinicians in the diagnostic process, especially when a broader genomic analysis is not required.

• ThyGeNEXT

  This oncogenic mutation panel is utilized to identify malignant thyroid nodules effectively. ThyGeNEXT applies cutting-edge genomic technology to analyze thyroid nodule samples, identifying mutations and rearrangements that indicate malignancy, thus enabling more accurate diagnosis and personalized treatment planning.

• ThyraMIR

  ThyraMIR utilizes a proprietary microRNA gene-expression assay to assess the risk of malignancy in thyroid nodules. This innovative test provides clinicians with a powerful tool in differentiating between benign and malignant thyroid conditions, enhancing the decision-making process for potential surgical interventions.

• RespriDx

  Designed to aid physicians in differentiating between metastatic or recurrent lung cancer, RespriDx is a genomic test that empowers healthcare providers with critical insights into the nature of lung lesions. This diagnostic tool plays a key role in determining the appropriate path for patient management and treatment strategies.